Abstract:Background: The use of single-chain variable fragments (scFvs) for treating human diseases, such as cancer and immune system disorders, has attracted significant attention. However, a critical drawback of scFv is its extremely short serum half-life, which limits its therapeutic potential. Thus, there is a critical need to prolong the serum half-life of the scFv for clinical applications. One promising serum half-life extender for therapeutic proteins is human serum albumin (HSA), which is the most abundant protein in human serum, known to have an exceptionally long serum half-life. However, conjugating a macromolecular half-life extender to a small protein, such as scFv, often results in a significant loss of its critical properties. Results: In this study, we conjugated the HSA to a permissive site of scFv to improve pharmacokinetic profiles. To ensure minimal damage to the antigen-binding capacity of scFv upon HSA conjugation, we employed a site-specific conjugation approach using a heterobifunctional crosslinker that facilitates thiol-maleimide reaction and inverse electron-demand Diels-Alder reaction (IEDDA). As a model protein, we selected 4D5scFv, derived from trastuzumab, a therapeutic antibody used in human epithermal growth factor 2 (HER2)-positive breast cancer treatment. We introduced a phenylalanine analog containing a very reactive tetrazine group (frTet) at conjugation site candidates predicted by computational methods. Using the linker TCO-PEG4-MAL, a single HSA molecule was site-specifically conjugated to the 4D5scFv (4D5scFv-HSA). The 4D5scFv-HSA conjugate exhibited HER2 binding affinity comparable to that of unmodified 4D5scFv. Furthermore, in pharmacokinetic profile in mice, the serum half-life of 4D5scFv-HSA was approximately 12 h, which is 85 times longer than that of 4D5scFv. Conclusions: The antigen binding results and pharmacokinetic profile of 4D5scFv-HSA demonstrate that the site-specifically albumin-conjugated scFv retained its binding affinity with a prolonged serum half-life. In conclusion, we developed an effective strategy to prepare site-specifically albumin-conjugated 4D5scFv, which can have versatile clinical applications with improved efficacy.

New Directions for Half-Life Extension of Protein Therapeutics: the Rise of Antibody Fc Domains and Fragments

Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins

Half-life extended biotherapeutics

Albumin-binding as a universal strategy for half-life extension

Engineered Fc Based Antibody Domains and Fragments As Novel Scaffolds.

Half-life extension using serum albumin-binding DARPin® domains

Application of Fusion Protein Technique in Development of Long-acting Drugs

Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

Protein Engineering Strategies for Improved Pharmacokinetics

Research Progress on Long-Term Protein and Polypeptide Drugs Technology

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life

Progression of the Long-term Mechanism and Pharmacokinetics Analysis Technology of Fusion Protein Drugs

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Antibody Conjugates-Recent Advances and Future Innovations

Half-Life Extension and Biodistribution Modulation of Biotherapeutics via Red Blood Cell Hitch-Hiking with Novel Anti-Band 3 Single-Domain Antibodies

New protein engineering approaches to multivalent and bispecific antibody fragments

Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation

Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

The Potential of Single-Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics